Publications by authors named "David Dinh Tran"
Background: Src signaling is markedly upregulated in patients with invasive glioblastoma (GBM) after the administration of bevacizumab. The Src family kinase inhibitor dasatinib has been found to effectively block bevacizumab-induced glioma invasion in preclinical models, which led to the hypothesis that combining bevacizumab with dasatinib could increase bevacizumab efficacy in patients with recurrent GBM.
Methods: After the completion of the phase 1 component, the phase 2 trial (ClinicalTrials.
Article Synopsis
- Recurrent glioblastoma multiforme (GBM) has a poor prognosis, but the NovoTTF-100A™ System has shown improved overall survival compared to previous trials, offering a median of 9.6 months versus 6.6 months in traditional therapies.
- Data from a post-marketing registry (PRiDe) involving 457 patients indicated that higher daily compliance and better performance status positively influenced survival rates, with higher one- and two-year survival rates compared to earlier trial results.
- Adverse events were primarily mild to moderate skin reactions, similar to those reported in prior studies, with no new safety concerns identified.
Calcium modulating cyclophilin ligand (CAML) is a ubiquitously expressed cytoplasmic protein that is implicated in the EGFR and LCK signaling pathways and required for early embryonic and thymocyte development. To further define the critical biological functions of CAML at the cellular level, we generated CAML-deleted mouse embryonic fibroblasts (MEFs) using an in vitro Cre-loxP mediated conditional knockout system. We found that CAML(-/-) MEFs have severely impaired proliferation and a strong reduction of normal anaphases.
View Article and Find Full Text PDF